TIL Therapy Plus IL-2 as Second-Line Treatment for Advanced Melanoma
Source: Cancer Therapy Advisor, July 2024
Tumor-infiltrating lymphocyte (TIL) therapy in combination with high-dose interleukin-2 (IL-2) should be considered as a second-line treatment of choice for patients with advanced melanoma who have received anti-PD-(L)1 therapy, according to researchers.
Via a meta-analysis, the researchers found that TIL therapy plus high-dose IL-2 produced similar response and survival outcomes whether patients had received prior anti-PD-(L)1 therapy or not. These findings were published in the Annals of Oncology.
The meta-analysis included 13 studies encompassing a total of 702 patients with advanced melanoma. In all studies, patients received TIL therapy and high-dose IL-2 after lymphodepleting chemotherapy.